Winnie Janssens

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa

T. Vesikari, N. Mesaros, B. Cheuvart, 2017, Human vaccines & immunotherapeutics.

Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer

N. Mesaros, Winnie Janssens, L. Hanssens, 2018, Expert review of vaccines.

Hexavalent vaccines: What can we learn from head-to-head studies?

Piyali Mukherjee, M. Knuf, Winnie Janssens, 2021, Vaccine.

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

S. Kuriyakose, N. Meyer, Winnie Janssens, 2020, Human vaccines & immunotherapeutics.

Infant vaccine co-administration: review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines

A. Mihályi, Winnie Janssens, J. Dolhain, 2020, Expert review of vaccines.

Long-term antibody persistence against hepatitis B in adolescents 14–15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy

N. Mesaros, T. Schwarz, Winnie Janssens, 2018, Human vaccines & immunotherapeutics.

Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States

N. Mesaros, N. Klein, B. Cheuvart, 2019, Human vaccines & immunotherapeutics.